MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592843 | Name: Amosulalol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amosulalol is an Adrenergic Agent.

Chemical Structure

Amosulalol
Amosulalol
CAS#85320-68-9

Theoretical Analysis

MedKoo Cat#: 592843

Name: Amosulalol

CAS#: 85320-68-9

Chemical Formula: C18H24N2O5S

Exact Mass: 380.1406

Molecular Weight: 380.46

Elemental Analysis: C, 56.83; H, 6.36; N, 7.36; O, 21.03; S, 8.43

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Amosulalol
IUPAC/Chemical Name
(+-)-5-(1-Hydroxy-2-((2-(o-methoxyphenoxy)ethyl)amino)ethyl)-o-toluenesulfonamide
InChi Key
LVEXHFZHOIWIIP-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
SMILES Code
CC1=CC=C(C(O)CNCCOC2=CC=CC=C2OC)C=C1S(=O)(N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 380.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jin WL, Azuma K, Mita T, Goto H, Kanazawa A, Shimizu T, Ikeda F, Fujitani Y, Hirose T, Kawamori R, Watada H. Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia. 2011 Jul;54(7):1921-9. doi: 10.1007/s00125-011-2141-5. Epub 2011 Apr 16. PubMed PMID: 21499675. 2: Suzuki K, Kamimura H. Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. Biol Pharm Bull. 2007 Aug;30(8):1580-5. PubMed PMID: 17666826. 3: Gwak HS, Noh ES, Lee NY, Chun IK. Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Apr 25;818(2):109-13. PubMed PMID: 15734149. 4: Ueyama T, Aki T, Senba E, Hatanaka K, Yoshida K. Emotional stress activates MAP kinase in the rat heart. Life Sci. 2001 Sep 7;69(16):1927-34. PubMed PMID: 11693273. 5: Nakamura T, Maruyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T. Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta. Pharmacology. 1999 Nov;59(5):234-8. PubMed PMID: 10529655. 6: Tamaki Y, Araie M, Muta K. Effect of topical amosulalol on tissue circulation in the optic nerve head. J Ocul Pharmacol Ther. 1999 Jun;15(3):217-24. PubMed PMID: 10385130. 7: Maruyama K, Nakamura T, Yoshihara T, Fukutomi J, Sugiyama K, Hattorim K, Ohnuki T, Watanabe K, Nagatomo T. Tamsulosin: assessment of affinity of 3H-prazosin bindings to two alpha1-adrenoceptor subtypes (alpha1H and alpha1L) in bovine prostate and rat heart and brain. Gen Pharmacol. 1998 Oct;31(4):597-600. PubMed PMID: 9792222. 8: Takada S, Numabe A, Hirawa N, Yagi S, Uehara Y. Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat. Prostaglandins Leukot Essent Fatty Acids. 1997 Feb;56(2):127-34. PubMed PMID: 9051722. 9: Taniguchi T, Deguchi T, Ogawa T, Kitazawa Y. [Effects of amosulalol hydrochloride on intraocular pressure and aqueous humor dynamics in the rabbit eye]. Nippon Ganka Gakkai Zasshi. 1996 Apr;100(4):279-83. Japanese. PubMed PMID: 8644539. 10: Asakuma S, Ohyanagi M, Iwasaki T. The effects of antianginal drugs on energy expenditure during exercise in normal subjects. Jpn Circ J. 1995 Mar;59(3):137-45. PubMed PMID: 7602749. 11: Inagaki O, Sudoh K, Shibasaki M, Nakagawa C, Honda K. Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. J Cardiovasc Pharmacol. 1994 Nov;24(5):794-802. PubMed PMID: 7532758. 12: van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. Review. PubMed PMID: 7684671. 13: Hayase N, Chiba K, Ichihara K. Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. PubMed PMID: 8095542. 14: Kinami J, Tsuchihashi H, Maruyama K, Sasaki K, Nagatomo T. Nipradilol displays a unique pharmacological profile of affinities for the different alpha 1-adrenoceptor subtypes. Jpn J Pharmacol. 1993 Feb;61(2):81-6. PubMed PMID: 7681491. 15: Doggrell SA. The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. PubMed PMID: 8095397. 16: Ando K, Noda H, Ogata E, Fujita T. Hemodynamic and endocrine changes associated with hypotensive action of amosulalol in essential hypertension. J Cardiovasc Pharmacol. 1992 Jul;20(1):7-10. PubMed PMID: 1383633. 17: Inoue Y, Yaga K, Nishimura M, Okafuji K, Fujii Y, Nagasaka Y, Tanaka M, Fujita N, Kaku K, Kaneko T, et al. Antihypertensive and metabolic effects of long-term treatment with amosulalol in non-insulin dependent diabetics. Curr Med Res Opin. 1992;12(9):564-71. PubMed PMID: 1582238. 18: Tanaka S, Miyabe M, Ohyama I, Seki S, Tsukamoto T, Namiki A. [Sevoflurane with continuous epidural anesthesia for removal of pheochromocytoma]. Masui. 1991 Aug;40(8):1261-4. Japanese. PubMed PMID: 1920806. 19: Yamaguchi T, Irisawa C, Watanabe H, Kawamura S, Nakada T. Failure of blood pressure control by a new combined alpha- and beta-blocking agent (amosulalol) in a patient with pheochromocytoma. Int Urol Nephrol. 1991;23(3):209-14. PubMed PMID: 1889965. 20: Strein K, Sponer G. Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule. Z Kardiol. 1990;79 Suppl 3:89-98. Review. PubMed PMID: 1983054.

View History

Amoxydramine camsilate

Amoxydramine camsilate